Opinion|Videos|May 31, 2024
Insights from CARTITUDE-4 and KarMMa-3 in R/R MM
Experts on multiple myeloma provide their impressions of the CARTITUDE-4 and KarMMa-3 studies, which led to the approval of cilta-cel and ide-cel in earlier lines of treatment for patients with relapsed/refractory disease.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Briefly review the CARTITUDE-4 trial that led to cilta-cel’s approval in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM).
- Please comment on the patient population – intention-to-treat vs patients treated.
- What was the rationale for the difference? How does it affect your interpretation of the data?
- How did the safety outcomes compare with other CARTITUDE trials?
- Please share your real-world experience.
- Please review data from KarMMa-3, which led to ide-cel’s approval in earlier lines of therapy for R/R MM.
- What are thoughts on the efficacy and safety outcomes?
- Please share your real-world experience.
- How do these approvals impact the current and future treatment landscape of R/R MM?
- How might you choose one over the other?
- How does it address an unmet need?
Advertisement
Related to this article
C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Lirafugratinib Approval Adds a Third FGFR2 Inhibitor in Cholangiocarcinoma
5